Drawing for ALLUCENT

USPTO serial 97978222

ALLUCENT

Reviewed by CopyMark Law Group

Reg. 7464174Status 700Registered
Filing date
Status date
Registration date
Jul 30, 2024
Examiner
IN, SUNG HYUN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ALLUCENT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Becky Troutman

Laura M. Franco Winston & Strawn LLP101 CALIFORNIA STREETSAN FRANCISCO, CA 94111United States

Goods and services

ClassDescriptionStatusFirst use
035Data management, namely, abstraction services in the nature of extracting and summarizing information from clinical trial records and collection of medical data from clinical tests and records for business purposes; Market research and business marketing consulting services in the pharmaceutical, biotechnology, medical device, and diagnostics industries; Data management, namely, the management for others of databases of patient health dataACTIVEMay 1, 2022
041Training and development in the field of conducting clinical trials, namely, conducting tutorials, seminars and workshops in the field of clinical trials; training in the field of computer software support, namely, conducting tutorials, seminars and workshops in the field of software supportACTIVEMay 1, 2022
042Cloud computing featuring software that allows users to collect, review, analyze and report on clinical research; technical support services, namely, installation and remote administration of software, and troubleshooting of software problems and hosted software applications, all for use in connection with medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; cloud computing featuring software for providing telehealth, telemedicine, remote care and virtual health care services to patients; cloud computing featuring software that allows users to collect, track, retrieve, validate, summarize, statistically analyze and present data used in the areas of medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; Cloud computing featuring software to aggregate, integrate, transfer and manage data generated from home health and remote monitoring devices and applications and health-related smart-phone applications; Cloud computing featuring software that provides integrated workflows, analytics, visualizations, and reporting features to deliver, process, analyze, elevate, and display patient-generated health data; Cloud computing featuring software that integrates remotely collected health data into databases, systems, platforms, applications, and software that inform clinical research, remote monitoring, and care management; technical consulting services, namely, evaluating the safety of pharmaceutical, medical, cosmetic and consumer devices and products in clinical development or in commercial production; Consulting services for others in the fields of design, planning, implementation and project management of clinical trials; Scientific analysis of statistical and qualitative data relating to clinical trials for pharmaceuticals, biotechnology, medical devices and diagnostics for scientific research and for the development of pharmaceutical, biotechnology, medical device and diagnostic products and methods of use of such devices and productsACTIVEMay 1, 2022
045Development of regulatory compliance strategies in the field of medical research, namely, regulatory compliance consulting in the field of drug, biologic, cosmetic and medical device developmentACTIVEMay 1, 2022

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 30, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jul 30, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 25, 2024SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 25, 2024CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jun 25, 2024DOCKASSIGNED TO EXAMINER—
May 21, 2024SUPCSTATEMENT OF USE PROCESSING COMPLETE—
May 21, 2024DPCCDIVISIONAL PROCESSING COMPLETE—
May 2, 2024AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 11, 2024IUAFUSE AMENDMENT FILED—
Apr 11, 2024DRRRDIVISIONAL REQUEST RECEIVED—
Apr 11, 2024ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Apr 11, 2024EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 11, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 11, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 11, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 4, 2024EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Apr 4, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 4, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 4, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 27, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 26, 2024EX1GSOU EXTENSION 1 GRANTED—
Mar 26, 2024EXT1SOU EXTENSION 1 FILED—
Mar 26, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 31, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 5, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 5, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 16, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 29, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 29, 2023XAECEXAMINER'S AMENDMENT ENTERED—
Jul 29, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 29, 2023GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 29, 2023CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 13, 2023ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jul 13, 2023PBSRWITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST—
Jul 3, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 22, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 21, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 21, 2023ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 16, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 16, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 16, 2023CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 6, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 6, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 6, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 6, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 6, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 6, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 4, 2023LOPRLETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN—
Dec 28, 2022DOCKASSIGNED TO EXAMINER—
Nov 21, 2022LOPTLETTER OF PROTEST EVIDENCE FORWARDED—
Apr 27, 2022MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 26, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 23, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance